Open Access Government produces compelling and informative news, publications, eBooks, and academic research articles for the public and private sector looking at health, diseases & conditions, workplace, research & innovation, digital transformation, government policy, environment, agriculture, energy, transport and more.
Home 2024
Archives
E. coli genomes, big data, and messy biology
Here, David Ussery from the Department of BioMedical Informatics, UAMS, details E. coli genome diversity, big data, and messy biology. New methods, we discover, allow for the comparison of millions of bacterial genomes in a few days and the confident assignment of taxonomic clusters.
Cellular scaffolding: Crowdsourcing cellular responses in health and disease
In this article, Dr Alan Herbert discusses how different types of cellular scaffolds interact and impact the risk of diseases, citing the example of Z-RNAs pushing cells to inflammatory states in tumors and autoimmune conditions, setting the stage for new therapeutics.
Asbestos disease pathogenesis: The long and short of it
Jean Pfau and Kinta Serve explore a critical and novel hypothesis concerning the size of fibers in asbestos disease pathogenesis.
The impact of juvenile onset rheumatic and musculoskeletal diseases on education, vocation and employment
Professor Suzanne Verstappen discusses the impact and challenges associated with juvenile-onset rheumatic and musculoskeletal diseases when navigating education and employment.
The challenge of generating lasting mucosal anti-viral sterilising immunity
Achieving sterilising immunity is often challenging and sometimes even impossible. This article gives a glimpse into the concepts behind and highlights some recent advances and challenges.
Protein kinases for combating inflammatory disease
Julie Blaising, Discovery Project Leader in Immunology at F. Hoffmann-La Roche Ltd, tells us why protein kinases are an effective target for treating many chronic inflammatory disorders.
Symptomatic vs. Disease-modifying treatments in neurological diseases: Where next?
An optimal drug for chronic neurological disease would slow down disease progression in the long term, with short-term symptomatic benefits. This would shorten clinical development timelines and reduce the cost and risk level for drug developers. Henri Huttunen Chief Scientific Officer (CSO) at Herantis Pharma Plc explains.
Getting leptospirosis onto the lists of neglected tropical diseases
Leptospirosis is a globally important infectious disease, but neglected to the extent that it’s not on WHO’s or FDA’s neglected tropical diseases lists; this needs to change.
Therapeutic potential of the endocannabinoid system to treat chronic pain in inflammatory disease
Pharma researchers Julie Blaising and Philip Smith from F. Hoffmann-La Roche Ltd. discuss the endocannabinoid system as a pathway to treat inflammatory diseases such as Inflammatory Bowel Disease (IBD) and endometriosis.
Collaborative governance on big health problems in developing countries
Collaborative governance research may help tackle big health problems in developing countries, says Michael P. Ryan. Here, he explains how.
Meteorological data for public health surveillance
Michael Wimberly, Professor from the University of Oklahoma, walks us through integrating meteorological data for public health surveillance and disease forecasting.
Navigating koala conservation challenges with advanced tech and game-changing vaccine research
Discover the intricate tale of koala survival, from habitat struggles to the rise of Chlamydia vaccines, in this exclusive interview with Professor Peter Timms from The University of Sunshine Coast, Australia.
MAGL inhibition: A novel treatment option for combating inflammatory disease?
Pharma researchers Uwe Grether and Julie Blaising from F. Hoffmann-La Roche Ltd. highlight the vast therapeutic potential of MAGL inhibition for central and peripheral diseases.
MPOX: Research priorities for threat reduction
Concerted efforts are needed to close knowledge gaps around mpox to improve preparedness and response efforts for this neglected disease.
Sepsis and the killer platelets
Dermot Cox BSc, PG Dip Ed, PhD, Pharmacology Lead from the School of Pharmacy and Biomolecular Sciences – RCSI University of Medicine & Health Sciences, discusses sepsis and the killer platelets.
Revolutionising disease detection: The emergence of non-invasive VOC breathomics
Breathomics marks a revolutionary approach to disease detection by analyzing the chemical composition of exhaled breath.
Mongolia and the One Health Approach
Mongolia’s unique ecosystems and cultures come with an equally unique set of wildlife management challenges.
The future of AVS, dizziness and vertigo in emergency departments: Part I. Towards a...
In this first of five articles, Dr Millie Nakatsuka discusses the socio-economic implications associated with the diagnosis of acute vestibular syndrome and why more cost-effective and sustainable approaches are needed.
Lessons from Libby: Understanding the impact of asbestos exposure
Jean C. Pfau, Scientific Consultant at the Center for Asbestos Related Disease, shares the devasting story of asbestos exposure occurring in a Rocky Mountain town of Montana and the critical lessons that can be learned from this event.
Sepsis Canada: Building a national research network for sepsis awareness
Sepsis is a life-threatening condition estimated to affect 49 million people annually worldwide; yet it is not widely understood. In this article, we hear how Sepsis Canada is working to promote sepsis awareness through supporting research, public education, and cross-disciplinary training.
